liarozole has been researched along with cyproterone acetate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Denis, L | 1 |
| Boccardo, F; Brune, D; Bruynseels, J; De Porre, P; Debruyne, FJ; Denis, L; Fradet, Y; Janssens, M; Johansson, JE; Marberger, JM; Murray, R; Rassweiler, J; Tyrrell, C; Vangeneugden, T | 1 |
2 trial(s) available for liarozole and cyproterone acetate
| Article | Year |
|---|---|
European Organization for Research and Treatment of Cancer (EORTC) prostate cancer trials, 1976-1996.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Castration; Cyproterone Acetate; Diethylstilbestrol; Doxorubicin; Epirubicin; Estramustine; Flutamide; Humans; Imidazoles; Male; Medroxyprogesterone Acetate; Methotrexate; Mitomycin; Neoplasms, Hormone-Dependent; Procarbazine; Prostatic Neoplasms; Vindesine | 1998 |
Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Cyproterone Acetate; Disease Progression; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate | 1998 |